You're one step closer to unlocking our suite of comprehensive and robust tools.
Fill out the form so we can connect you to the right person.
Recent awards include:
If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.
Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.
At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.
STAAR Surgical closes common stock offering
COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021
Climate Credit Analytics: Linking climate scenarios to financial impacts
Global M&A Infographic Q1 2021
Q1 2021 Global Capital Markets Activity: SPAC IPOs, Issuance in Consumer Discretionary Sector Surge
STAAR Surgical Co. closed an underwritten public offering of 1,999,850 common shares priced at $39 apiece, raising gross proceeds of about $78 million.
The shares sold include the full exercise of the underwriter's option to buy up to an additional 260,850 common shares in the offering.
Monrovia, Calif.-based STAAR Surgical develops and manufactures implantable lenses and companion delivery systems for the eye.
Canaccord Genuity acted as the sole book-running manager for the transaction.